Nutraceuticals, a call for quality control of delivery systems: A case study with chondroitin sulfate and glucosamine

Journal of Nutraceuticals, Functional and Medical Foods

Volumn 2, Issue 2, 2000, Pages 15-30

  Adebowale, Abimbola O ^a   Liang, Zhongming ^a   Eddington, Natalie D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Chondroitin sulfate; Content uniformity; Glucosamine; Nutraceutical delivery systems; Standardization

Indexed keywords

CHONDROITIN SULFATE; GLUCOSAMINE;

ARTICLE; DIET SUPPLEMENTATION; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG QUALITY; OSTEOARTHRITIS; QUALITY CONTROL;

EID: 0033398642     PISSN: 10894179     EISSN: None     Source Type: Journal    
DOI: 10.1300/j133v02n02_03     Document Type: Article

References (22)

1. Adebowale, A., Z. Liang, et al. (1997). Development and Validation of a High Performance Size Exclusion Chromatographic Method for the Quantitation of Chondroitin Sulfate in Raw Materials and Dosage Forms, Annual Association of Pharmaceutical Scientists 11th National Meeting, Boston, MA.
2. Baici, A. and P. Bradamante (1984). "Interaction between human leukocyte elastase and chondroitin sulfate." Chemico-Biological Interactions 51: 1-11.
3. Bassleer, C., Y. Henrotin, et al. (1992). "In vitro evaluation of drugs proposed as chondroprotective agents." International Journal of Tissue Reactions 14: 231-241.
4. Bucci, L. R. (1994, January). "Chondroprotective agents: Glucosamine salts and Chondroitin sulfates." Townsend Letter Document, 52-54.
5. Burkhardt, D. and P. Ghosh (1987). "Laboratory evaluation of antiarthritic drugs as potential chondroprotective agents." Seminars in Arthritis and Rheumatism 17: 3-34.
6. Butterworth, C. E. and A. Bendich (1996). "Folic acid and the prevention of birth defects." Annual Review of Nutrition 16: 73-97.
7. Carr, C. J. and R. F. Shangraw (1987). "Nutritional and pharmaceutical aspects of calcium supplementation." Am-Pharm NS27(Feb): 49-50, 54-57.
8. Defelice, S. (1995). NUTRACEUTICALS "Expert predicts 250 in Market." OTC Update.
9. Fioravanti, A., A. Franci, et al. (1991). "Clinical efficacy and tolerance of galactosaminoglycan sulfate in the treatment of osteoarthritis." Drugs Under Experimental and Clinical Research 17: 41-44.
10. Foundation for Innovation in Medicine (1993, January). "The Nutraceutical Initiative part 1." The Nutrition and Dietary Consultant: 11 and 19.
11. Gosh, P., M. Smith, et al. (1992). "Second-line agents in osteoarhtritis." Second-Line Agents in the Treatment of Rheumatic Diseases. New York, Marcel Dekker: 363-427.
12. Lawrence, R. C., T. A. Medsger, Jr., et al. (1989). "Estimates of the prevalence of selected arthritic and muscoskeletal diseases in the United States." Journal of Rheumatology 16.
13. Liang, Z., J. Leslie et al. (1999). "Determination of the nutraceutical, glucosamine hydrochloride, in raw materials, dosage forms and plasma using pre-column derivatization with ultraviolet HPLC." J Pharmaceut Biomed Anal; in press.
14. McCarty, M. F. (1994). "The neglect of glucosamine as atreatment for osteoarthritis-A personal perspective." Medical Hypotheses 42: 323-327.
15. McNamara, S. H. (1997). "Dietary supplement legislation enhances opportunities to market 'Nutraceutical'-type products." Journal of Nutraceuticals. Functional and Medical Foods 1(1): 47-59.
16. Miller, L. (1993, September), "News analysis: U.S. lags in nutraceutical development." Biotechnology 11: 969-972.
17. Paroli, E., L. Antonilli, et al. (1991). "A pharmacological approach to glycosaminoglycan." Drugs Under Experimental and Clinical Research xvii: 9-20.
18. Pipitone, V. R. (1991). "Chondroprotection with chondroitin sulfate." Drugs Under Experimental and Clinical Research xvii: 3-7.
19. Reichelt, A., K. K. Forster, et al. (1994). "Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee." Arzneimittel Forschung 44: 75-80.
20. Smith, B. L., M. Marcotte, et al. (1997). "A comparative analysis of the regulatory framework affecting functional food development and commercialization in Canada, Japan, the European Union and the United States of America." Journal of Nutraceuticals, Functional and Medical Foods 1(2): 45-87.
21. The U.S. Pharmacopoeia (1995). Guide to General Chapters Nutritional Supplement. The United States Pharmacopoeia 23/ National Formulary 18. Rockville, Maryland, United States Pharmacopoeial Convention, Inc.: 2179-2192.
22. The U.S. Pharmacopoeia (1995). Uniformity of Dosage Units. Rockville, Maryland, United States Pharmacopoeial Convention, Inc.